Formation and Reactions of Xenobiotic Quinone Methides in Biology

Quinone Methides

Volumn , Issue , 2009, Pages 329-356

  Bolton, Judy L ^a   Thompson, John A ^b  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^b UNIVERSITY OF COLORADO   (United States)

Author keywords

Alkylphenols BHT and related alkylphenols; Formation and reactions of xenobiotic quinone methides in biology; Methoxyphenols and catechols

Indexed keywords

EID: 84889320965     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9780470452882.ch10     Document Type: Chapter

References (101)

1. Thompson, D. C.; Thompson, J. A.; Sugumaran, M.; Moldeus, P. Biological and toxicological consequences of quinone methide formation. Chem.-Biol. Interact. 1993, 86, 129-162.
2. Peter,M.G. Chemical modifications of bio-polymers by quinones and quinone methides. Angew. Chem. Int. Ed. 1989, 28, 555-570.
3. Monks, T. J.; Jones, D. C. The metabolism and toxicity of quinones, quinonimines, quinone methides, and quinone-thioethers. Curr. Drug Metab. 2002, 3, 425-438.
4. Monks, T. J.; Hanzlik, R. P.; Cohen, G. M.; Ross, D.; Graham, D. G. Quinone chemistry and toxicity. Toxicol. Appl. Pharmacol. 1992, 112, 2-16.
5. Richard, J. P.; Amyes, T. L.; Bei, L.; Stubblefield, V. The effect of beta-fluorine substituents on the rate and equilibrium-constants for the reactions of alpha-substituted 4-methoxybenzyl carbocations and on the reactivity of a simple quinone methide. J. Am. Chem. Soc. 1990, 112, 9513-9519.
6. Hulbert, P. B.; Grover, P. L. Chemical rearrangement of phenol-epoxide metabolites of polycyclic aromatic hydrocarbons to quinone-methides. Biochem. Biophys. Res. Commun. 1983, 117, 129-134.
7. Dowers, T. S.; Qin, Z. H.; Thatcher,G. R.; Bolton, J. L. Bioactivation of selective estrogen receptor modulators (SERMs). Chem. Res. Toxicol. 2006, 19, 1125-1137.
8. Bolton, J. L.; Acay, N. M.; Vukomanovic, V. Evidence that 4-allyl-o-quinones spontaneously rearrange to their more electrophilic quinone methides: potential bioactivation mechanism for the hepatocarcinogen safrole. Chem. Res. Toxicol. 1994, 7, 443-450.
9. Iverson, S. L.; Hu, L. Q.; Vukomanovic, V.; Bolton, J. L. The influence of the para-alkyl substituent on the isomerization of o-quinones to p-quinone methides: potential bioactivation mechanism for catechols. Chem. Res. Toxicol. 1995, 8, 537-544.
10. Bolton, J. L.; Thatcher, G. R. Potential mechanisms of estrogen quinone carcinogenesis. Chem. Res. Toxicol. 2008, 21, 93-101.
11. Born, T. L.; Myers, J. K.;Widlanski, T. S.; Rusnak, F. 4-(Fluoromethyl)phenyl phosphate acts as a mechanism-based inhibitor of calcineurin. J. Biol. Chem. 1995, 270, 25651-25655.
12. Thompson, D. C.; Perera, K.; London, R. Spontaneous hydrolysis of 4-trifluoromethylphenol to a quinone methide and subsequent protein alkylation. Chem.-Biol. Interact. 2000, 126, 1-14.
13. Witschi, H.; Lock, S. Toxicity of butylated hydroxytoluene in mouse following oral administration. Toxicology 1978, 9, 137-146.
14. Witschi, H.; Malkinson, A. M.; Thompson, J. A. Metabolism and pulmonary toxicity of butylated hydroxytoluene (BHT). Pharmacol. Ther. 1989, 42, 89-113.
15. Malkinson, A. M.; Koski, K. M.; Evans,W. A.; Festing, M. F. Butylated hydroxytoluene exposure is necessary to induce lung tumors in BALB mice treated with 3-methylcholanthrene. Cancer Res. 1997, 57, 2832-2834.
16. Bauer, A. K.; Dwyer-Nield, L. D.; Keil, K.; Koski, K.; Malkinson, A. M. Butylated hydroxytoluene (BHT) induction of pulmonary inflammation: a role in tumor promotion. Exp. Lung Res. 2001, 27, 197-216.
17. Bauer, A. K.; Dwyer-Nield, L. D.; Hankin, J. A.; Murphy, R. C.; Malkinson, A. M. The lung tumor promoter, butylated hydroxytoluene (BHT), causes chronic inflammation in promotion-sensitive BALB/cByJ mice but not in promotion-resistant CXB4 mice. Toxicology 2001, 169, 1-15.
18. Malkinson, A. M. Primary lung tumors in mice: an experimentally manipulable model of human adenocarcinoma. Cancer Res. 1992, 52, 2670s-2676s.
19. Kehrer, J. P.; Witschi, H. Effects of drug metabolism inhibitors on butylated hydroxytoluene- induced pulmonary toxicity in mice. Toxicol. Appl. Pharmacol. 1980, 53, 333-342.
20. Takahashi, O.; Hiraga, K. 2,6-Di-tert-butyl-4-methylene-2,5-cyclohexadienone: a hepatic metabolite of butylated hydroxytoluene in rats. Food Cosmet. Toxicol. 1979, 17, 451-454.
21. Bolton, J. L.; Sevestre, H.; Ibe, B. O.; Thompson, J. A. Formation and reactivity of alternative quinone methides from butylated hydroxytoluene: possible explanation for species-specific pneumotoxicity. Chem. Res. Toxicol. 1990, 3, 65-70.
22. Bolton, J. L.; Thompson, J. A. Oxidation of butylated hydroxytoluene to toxic metabolites: factors influencing hydroxylation and quinone methide formation by hepatic and pulmonary microsomes. Drug Metab. Dispos. 1991, 19, 467-472.
23. Mizutani, T.;Yamamoto, K.; Tajima, K. Isotope effects on the metabolism and pulmonary toxicity of butylated hydroxytoluene in mice by deuteration of the 4-methyl group. Toxicol. Appl. Pharm. 1983, 69, 283-290.
24. Thompson, D. C.; Perera, K.; London, R. Studies on the mechanism of hepatotoxicity of 4-methylphenol(p-cresol)-effects of deuterium labeling and ring substitution. Chem.-Biol. Interact. 1996, 101, 1-11.
25. Guyton, K. Z.; Bhan, P.; Kuppusamy, P.; Zweier, J. L.; Trush, M. A.; Kensler, T.W. Free radical-derived quinone methide mediates skin tumor promotion by butylated hydroxytoluene hydroperoxide: expanded role for electrophiles in multistage carcinogenesis. Proc. Natl. Acad. Sci. USA 1991, 88, 946-950.
26. Filar, L. J.; Winstein, S. Preparation and behavior of simple quinone methides. Tetrahedron Lett. 1960, 25, 9-16.
27. Mizutani, T.; Ishida, I.; Yamamoto, K.; Tajima, K. Pulmonary toxicity of butylated hydroxytoluene and related alkylphenols: structural requirements for toxic potency in mice. Toxicol. Appl. Pharmacol. 1982, 62, 273-281.
28. Bolton, J. L.; Valerio, L. G. J.; Thompson, J. A. The enzymatic formation and chemical reactivity of quinone methides correlate with alkylphenol-induced toxicity in rat hepatocytes. Chem. Res. Toxicol. 1992, 5, 816-822.
29. Thompson, J. A.; Carlson, T. J.; Sun, Y.; Dwyer-Nield, L. D.; Malkinson, A. M. Studies using structural analogs and inbred strain differences to support a role for quinone methide metabolites of butylated hydroxytoluene (BHT) in mouse lung tumor promotion. Toxicology 2001, 160, 197-205.
30. Sun,Y.; Dwyer-Nield, L. D.; Malkinson, A. M.; Zhang,Y. L.; Thompson, J. A. Responses of tumorigenic and non-tumorigenic mouse lung epithelial cell lines to electrophilic metabolites of the tumor promoter butylated hydroxytoluene. Chem.-Biol. Interact. 2003, 145, 41-51.
31. Kupfer, R.; Dwyer-Nield, L. D.; Malkinson, A. M.; Thompson, J. A. Lung toxicity and tumor promotion by hydroxylated derivatives of 2,6-di-tert-butyl-4-methylphenol (BHT) and 2-tert-butyl-4-methyl-6-iso-propylphenol: correlation with quinone methide reactivity. Chem. Res. Toxicol. 2002, 15, 1106-1112.
32. Guyton, K.; Dolan, P. M.; Kensler, T.W. Quinone methide mediates in vitro induction of ornithine decarboxylase by the tumor promoter butylated hydroxytoluene hydroperoxide. Carcinogenesis 1994, 15, 817-821.
33. Guyton, K. Z.; Gorospe, M.; Kensler, T. W.; Holbrook, N. J. Mitogen-activated protein kinase (MAPK) activation by butylated hydroxytoluene hydroperoxide: implications for cellular survival and tumor promotion. Cancer Res. 1996, 56, 3480-3485.
34. Desjardins, J. P.; Beard, S. E.; Mapoles, J. E.; Gee, P.; Thompson, J. A. Transcriptional activity of quinone methides derived from the tumor promoter butylated hydroxytoluene in HepG2 cells. Cancer Lett. 1998, 131, 201-207.
35. Bolton, J. L.; Turnipseed, S. B.; Thompson, J. A. Influence of quinone methide reactivity on the alkylation of thiol and amino groups in proteins: studies utilizing amino acid and peptide models. Chem.-Biol. Interact. 1997, 107, 185-200.
36. Guyton, K. Z.; Thompson, J. A.; Kensler, T. W. Role of quinone methide in the in vitro toxicity of the skin tumor promoter butylated hydroxytoluene hydroperoxide. Chem. Res. Toxicol. 1993, 6, 731-738.
37. Bolton, J. L.; Le Blanc, J. C.Y.; Siu, K.W. M. Reaction of quinone methides with proteins: analysis of myoglobin adduct formation by electrospray mass spectrometry. Biol. Mass Spectrom. 1993, 22, 666-668.
38. McCracken, P.G.; Bolton, J. L.; Thatcher, G. R. J. Covalent modification of proteins and peptides by the quinone methide from 2-tert-butyl-4,6-dimethylphenol: selectivity and reactivity with respect to competitive hydration. J. Org. Chem. 1997, 62, 1820-1825.
39. Meier, B.W.; Gomez, J. D.; Zhou, A.; Thompson, J. A. Immunochemical and proteomic analysis of covalent adducts formed by quinone methide tumor promoters in mouse lung epithelial cell lines. Chem. Res. Toxicol. 2005, 18, 1575-1585.
40. Meier, B. W.; Gomez, J. D.; Kirichenko, O. V.; Thompson, J. A. Mechanistic basis for inflammation and tumor promotion in lungs of 2,6-di-tert-butyl-4-methylphenol-treated mice: electrophilic metabolites alkylate and inactivate antioxidant enzymes. Chem. Res. Toxicol. 2007, 20, 199-207.
41. Lewis, M. A.; Yoerg, D. G.; Bolton, J. L.; Thompson, J. A. Alkylation of 20-deoxynucleosides and DNA by quinone methides derived from 2,6-di-tert-butyl-4-methylphenol. Chem. Res. Toxicol. 1996, 9, 1368-1374.
42. Reed, M.; Thompson, D. C. Immunochemical visualization and identification of rat liver proteins adducted by 2,6-di-tert-butyl-4-methylphenol (BHT). Chem. Res. Toxicol. 1997, 10, 1109-1117.
43. Lemercier, J. N.; Meier, B. W.; Gomez, J. D.; Thompson, J. A. Inhibition of glutathione S-transferase P1-1 in mouse lung epithelial cells by the tumor promoter 2,6-di-tert-butyl-4-methylene-2,5-cyclohexadienone (BHT-quinone methide): protein adducts investigated by electrospray mass spectrometry. Chem. Res. Toxicol. 2004, 17, 1675-1683.
44. Adler, V.; Yin, Z.; Fuchs, S. Y.; Benezra, M.; Rosario, L.; Tew, K. D.; Pincus, M. R.; Sardana, M.; Henderson, C. J.; Wolf, C. R.; Davis, R. J.; Ronai, Z. Regulation of JNK signaling by GSTp. EMBO J. 1999, 18, 1321-1334.
45. Modica, E.; Zanaletti, R.; Freccero, M.; Mella, M. Alkylation of amino acids and glutathione in water by o-quinone methide. Reactivity and selectivity. J. Org. Chem. 2001, 66, 41-52.
46. Kassahun, K.; Pearson, P. G.; Tang, W.; McIntosh, I.; Leung, K.; Elmore, C.; Dean, D.; Wang, R.; Doss, G.; Baillie, T. A. Studies on the metabolism of troglitazone to reactive intermediates in vitro and in vivo. Evidence for novel biotransformation pathways involving quinone methide formation and thiazolidinedione ring scission. Chem. Res. Toxicol. 2001, 14, 62-70.
47. IARC Monographs; International Agency for Research on Cancer: Lyon, France, 1985; Vol. 36, pp 75-97.
48. Thompson, D. C.; Constantin, T. D.; Moldeus, P. Metabolism and cytotoxicity of eugenol in isolated rat hepatocytes. Chem.-Biol. Interact. 1991, 77, 137-147.
49. Bodell, W. J.; Ye, Q.; Pathak, D. N.; Pongracz, K. Oxidation of eugenol to form DNA adducts and 8-hydroxy-20-deoxyguanosine: role of quinone methide derivative in DNA adduct formation. Carcinogenesis 1998, 19, 437-443.
50. Bolton, J. L.; Comeau, E.; Vukomanovic, V. The influence of 4-alkyl substituents on the formation and reactivity of 2-methoxy-quinone methides: evidence that extended p-conjugation dramatically stabilizes the quinone methide formed from eugenol. Chem.-Biol. Interact. 1995, 95, 279-290.
51. Mizutani, T.; Satoh, K.; Nomura, H. Hepatotoxicity of eugenol and related compounds in mice depleted of glutathione: structural requirements for toxic potency. Res. Commun. Chem. Pathol. Pharmacol. 1991, 73, 87-95.
52. Mizutani, T.; Satoh, K.; Nomura, H.; Nakanishi, K. Hepatotoxicity of eugenol in mice depleted of glutathione by treatment with DL-buthionine sulfoximine. Res. Commun. Chem. Pathol. Pharmacol. 1991, 71, 219-230.
53. Thompson, D. C.; Perera, K.; Krol, E. S.; Bolton, J. L. O-Methoxy-4-alkylphenols that form quinone methides of intermediate reactivity are the most toxic in rat liver slices. Chem. Res. Toxicol. 1995, 8, 323-327.
54. Betel-Quid and Areca Nut Chewing (IARC Monograph); International Agency for Research on Cancer: Lyon, France, 1985; Vol. 37, pp 141-291.
55. Benedetti, M. S.; Malnoe, A.; Broillet, A. L. Absorption, metabolism and excretion of safrole in the rat and man. Toxicology 1977, 7, 69-83.
56. Sakano, K.; Inagaki, Y.; Oikawa, S.; Hiraku, Y.; Kawanishi, S. Copper-mediated oxidative DNA damage induced by eugenol: possible involvement of O-demethylation. Mutat. Res. 2004, 565, 35-44.
57. Bolton, J. L.; Pisha, E.; Shen, L.; Krol, E. S.; Iverson, S. L.; Huang, Z.; van Breemen, R. B.; Pezzuto, J. M. The reactivity of o-quinones which do not isomerize to quinone methides correlates with alkylcatechol-induced toxicity in human melanoma cells. Chem.-Biol. Interact. 1997, 106, 133-148.
58. Potter, G. A.; McCague, R.; Jarman, M. A mechanistic hypothesis for DNA adduct formation by tamoxifen following hepatic oxidative metabolism. Carcinogenesis 1994, 5, 439-442.
59. Fan, P. W.; Zhang, F.; Bolton, J. L. 4-Hydroxylated metabolites of the antiestrogens tamoxifen and toremifene are metabolized to unusually stable quinone methides. Chem. Res. Toxicol. 2000, 13, 45-52.
60. Bolton, J. L.; Comeau, E.; Vukomanovic, V. The influence of 4-alkyl substituents on the formation and reactivity of 2-methoxy-quinone methides: evidence that extended piconjugation dramatically stabilizes the quinone methide formed from eugenol. Chem.-Biol. Interact. 1995, 95, 279-290.
61. McLuckie, K. I.; Routledge, M. N.; Brown, K.; Gaskell, M.; Farmer, P. B.; Roberts, G. C.; Martin, E. A. DNA adducts formed from 4-hydroxytamoxifen are more mutagenic than those formed by alpha-acetoxytamoxifen in a shuttle vector target gene replicated in human Ad293 cells. Biochemistry 2002, 41, 8899-8906.
62. Beland, F. A.; McDaniel, L. P.; Marques, M.M. Comparison of the DNA adducts formed by tamoxifen and 4-hydroxytamoxifen in vivo. Carcinogenesis 1999, 20, 471-477.
63. Marques, M. M.; Beland, F. A. Identification of tamoxifen-DNA adducts formed by 4-hydroxytamoxifen quinone methide. Carcinogenesis 1997, 18, 1949-1954.
64. Liu, J.; Liu, H.; van Breemen, R. B.; Thatcher, G. R.; Bolton, J. L. Bioactivation of the selective estrogen receptor modulator acolbifene to quinone methides. Chem. Res. Toxicol. 2005, 18, 174-182.
65. Yager, J. D.; Davidson, N. E. Estrogen carcinogenesis in breast cancer. N. Engl. J. Med. 2006, 354, 270-282.
66. Russo, J.; Hu,Y. F.;Yang, X.; Russo, I. H. Developmental, cellular, and molecular basis of human breast cancer. J. Natl. Cancer Inst. Monogr. 2000, 27, 17-37.
67. Jefcoate, C. R.; Liehr, J. G.; Santen, R. J.; Sutter, T. R.;Yager, J. D.;Yue,W.; Santner, S. J.; Tekmal, R.; Demers, L.; Pauley, R.; Naftolin, F.; Mor, G.; Berstein, L. Tissue-specific synthesis and oxidative metabolism of estrogens. J. Natl. Cancer Inst. Monogr. 2000, 27, 95-112.
68. Cavalieri, E.; Chakravarti, D.; Guttenplan, J.; Hart, E.; Ingle, J.; Jankowiak, R.; Muti, P.; Rogan, E.; Russo, J.; Santen, R.; Sutter, T. Catechol estrogen quinones as initiators of breast and other human cancers: implications for biomarkers of susceptibility and cancer prevention. Biochim. Biophys. Acta 2006, 1766, 63-78.
69. Russo, J.; Russo, I. H. The role of estrogen in the initiation of breast cancer. J. Steroid Biochem. Mol. Biol. 2006, 102, 89-96.
70. Henderson, B. E.; Feigelson, H. S. Hormonal carcinogenesis. Carcinogenesis 2000, 21, 427-433.
71. Feigelson, H. S.; Henderson, B. E. Estrogens and breast cancer. Carcinogenesis 1996, 17, 2279-2284.
72. Nandi, S.; Guzman, R. C.; Yang, J. Hormones and mammary carcinogenesis in mice, rats, and humans: a unifying hypothesis. Proc. Natl. Acad. Sci. USA 1995, 92, 3650-3657.
73. Flototto, T.; Djahansouzi, S.; Glaser, M.; Hanstein, B.; Niederacher, D.; Brumm, C.; Beckmann, M. W. Hormones and hormone antagonists: mechanisms of action in carcinogenesis of endometrial and breast cancer. Horm. Metab. Res. 2001, 33, 451-457.
74. Iverson, S. L.; Shen, L.; Anlar, N.; Bolton, J. L. Bioactivation of estrone and its catechol metabolites to quinoid-glutathione conjugates in rat liver microsomes. Chem. Res. Toxicol. 1996, 9, 492-499.
75. Bolton, J. L.; Shen, L. p-Quinone methides are the major decomposition products of catechol estrogen o-quinones. Carcinogenesis 1996, 17, 925-929.
76. Stack, D. E.; Byun, J.; Gross, M. L.; Rogan, E. G.; Cavalieri, E. L. Molecular characteristics of catechol estrogen quinones in reactions with deoxyribonucleosides. Chem. Res. Toxicol. 1996, 9, 851-859.
77. Bolton, J. L.; Yu, L.; Thatcher, G. R. Quinoids formed from estrogens and antiestrogens. Methods Enzymol. 2004, 378, 110-123.
78. Prokai-Tatrai, K.; Prokai, L. Impact of metabolism on the safety of estrogen therapy. Ann. N.Y. Acad. Sci. 1052, 2005, 243-257.
79. Liehr, J. G. Role of DNA adducts in hormonal carcinogenesis. Regul. Toxicol. Pharmacol. 2000, 32, 276-282.
80. Russo, J.; Russo, I. H. Genotoxicity of steroidal estrogens. Trends Endocrinol. Metab. 2004, 15, 211-214.
81. Li, K. M.; Todorovic, R.; Devanesan, P.; Higginbotham, S.; Kofeler, H.; Ramanathan, R.; Gross, M. L.; Rogan, E. G.; Cavalieri, E. L. Metabolism and DNA binding studies of 4-hydroxyestradiol and estradiol-3,4-quinone in vitro and in female ACI rat mammary gland in vivo. Carcinogenesis 2004, 25, 289-297.
82. Chakravarti, D.; Mailander, P. C.; Li, K. M.; Higginbotham, S.; Zhang, H. L.; Gross, M. L.; Meza, J. L.; Cavalieri, E. L.; Rogan, E. G. Evidence that a burst of DNA depurination inSENCARmouse skin induces error-prone repair and forms mutations in the H-ras gene. Oncogene 2001, 20, 7945-7953.
83. Cavalieri, E.; Frenkel, K.; Liehr, J. G.; Rogan, E.; Roy, D. Estrogens as endogenous genotoxic agents-DNA adducts and mutations. J. Natl. Cancer Inst. Monogr. 2000, 27, 75-93.
84. Saeed, M.; Rogan, E.; Fernandez, S. V.; Sheriff, F.; Russo, J.; Cavalieri, E. Formation of depurinating N3-adenine and N7-guanine adducts by MCF-10F cells cultured in the presence of 4-hydroxyestradiol. Int. J. Cancer 2007, 120, 1821-1824.
85. Zahid, M.; Kohli, E.; Saeed, M.; Rogan, E.; Cavalieri, E. The greater reactivity of estradiol-3,4-quinone vs. estradiol-2,3-quinone with DNA in the formation of depurinating adducts: implications for tumor-initiating activity. Chem. Res. Toxicol. 2006, 19, 164-172.
86. Debrauwer, L.; Rathahao, E.; Jouanin, I.; Paris, A.; Clodic, G.; Molines, H.; Convert, O.; Fournier, F.; Tabet, J. C. Investigation of the regio- and stereoselectivity of deoxyguanosine linkage to deuterated 2-hydroxyestradiol by using liquid chromatography/ESI-ion trap mass spectrometry. J. Am. Soc. Mass Spectrom. 2003, 14, 364-372.
87. Terashima, I.; Suzuki, N.; Shibutani, S. Mutagenic properties of estrogen quinone-derived DNA adducts in simian kidney cells. Biochemistry 2001, 40, 166-172.
88. Hayashi, N.; Hasegawa, K.; Barrett, J. C.; Tsutsui, T. Estrogen-induced cell transformation and DNA adduct formation in cultured Syrian hamster embryo cells. Mol. Carcinog. 1996, 16, 149-156.
89. Embrechts, J.; Lemiere, F.; Dongen, W. V.; Esmans, E. L.; Buytaert, P.; van Marck, E.; Kockx, M.; Makar, A. Detection of estrogen DNA-adducts in human breast tumor tissue and healthy tissue by combined nano LC-nano ES tandem mass spectrometry. J. Am. Soc. Mass Spectrom. 2003, 14, 482-491.
90. Rietjens, I. M.; Boersma, M. G.; van der Woude, H.; Jeurissen, S. M.; Schutte, M. E.; Alink, G. M. Flavonoids and alkenylbenzenes: mechanisms of mutagenic action and carcinogenic risk. Mutat. Res. 2005, 574, 124-138.
91. MacGregor, J. T.; Jurd, L. Mutagenicity of plant flavonoids: structural requirements for mutagenic activity in Salmonella typhimurium. Mutat. Res. 1978, 54, 297-309.
92. Brown, J. P. A review of the genetic effects of naturally occurring flavonoids, anthraquinolines and related compounds. Mutat. Res. 1980, 75, 243-277.
93. Boersma, M. G.; Vervoort, J.; Szymusiak, H.; Lemanska, K.; Tyrakowska, B.; Cenas, N.; Segura-Aguilar, J.; Rietjens, I. M. Regioselectivity and reversibility of the glutathione conjugation of quercetin quinone methide. Chem. Res. Toxicol. 2000, 13, 185-191.
94. Walle, T.; Vincent, T. S.; Walle, U. K. Evidence of covalent binding of the dietary flavonoid quercetin to DNA and protein in human intestinal and hepatic cells. Biochem. Pharmacol. 2003, 65, 1603-1610.
95. Yu, L.; Liu, H.; Li,W.; Zhang, F.; Luckie, C.; van Breemen, R. B.; Thatcher,G. R.; Bolton, J. L. Oxidation of raloxifene to quinoids: potential toxic pathways via a diquinone methide and o-quinones. Chem. Res. Toxicol. 2004, 17, 879-888.
96. Liu, H.; Liu, J.; van Breemen, R. B.; Thatcher, G. R.; Bolton, J. L. Bioactivation of the selective estrogen receptor modulator desmethylated arzoxifene to quinoids: 40-fluoro substitution prevents quinoid formation. Chem. Res. Toxicol. 2005, 18, 162-173.
97. Fiorelli, G.; Picariello, L.; Martineti, V.; Tonelli, F.; Brandi, M. L. Estrogen synthesis in human colon cancer epithelial cells. J. Steroid Biochem. Mol. Biol. 1999, 71, 223-230.
98. Chen, Q.; Ngui, J. S.; Doss, G. A.;Wang, R.W.; Cai, X.; DiNinno, F. P.; Blizzard, T. A.; Hammond, M. L.; Stearns, R. A.; Evans, D. C.; Baillie, T. A.; Tang,W. Cytochrome P450 3A4-mediated bioactivation of raloxifene: irreversible enzyme inhibition and thiol adduct formation. Chem. Res. Toxicol. 2002, 15, 907-914.
99. Baer, B. R.; Wienkers, L. C.; Rock, D. A. Time-dependent inactivation of P450 3A4 by raloxifene: identification of Cys239 as the site of apoprotein alkylation. Chem. Res. Toxicol. 2007, 20, 954-964.
100. Liu, J.; Li, Q.; Yang, X.; van Breemen, R. B.; Bolton, J. L.; Thatcher, G. R. Analysis of protein covalent modification by xenobiotics using a covert oxidatively activated tag: raloxifene proof-of-principle study. Chem. Res. Toxicol. 2005, 18, 1485-1496.
101. Liu, H.; Qin, Z.; Thatcher, G. R.; Bolton, J. L. Uterine peroxidase-catalyzed formation of diquinone methides from the selective estrogen receptor modulators raloxifene and desmethylated arzoxifene. Chem. Res. Toxicol. 2007, 20, 1676-1684.